mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. - Wikidata - awgldk - TriplyDB

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.

http://www.wikidata.org/entity/Q34360637

about

You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6 Hypoxia-inducible factors in cancer stem cells and inflammation.Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia - preliminary report Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.Blood transcriptome based biomarkers for human circadian phase.Mammalian target of rapamycin as a target in hematological malignancies.The clinical development of FLT3 inhibitors in acute myeloid leukemia.An overview of the mTOR pathway as a target in cancer therapy.Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia.Saffron (Crocus sativus) pretreatment confers cardioprotection against ischemia-reperfusion injuries in isolated rabbit heart.Modeling Protein Expression and Protein Signaling Pathways.A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

P2860

Q26998971-641CBF5B-E963-4E1C-8665-CDAAFAE41425 Q28078957-6141D142-BFA2-4902-BA98-E583482FEE6D Q33752594-FAC49F35-BB7D-44D4-A32E-FE29AAC1C6CA Q33882022-5F0CE03E-9CED-4E9B-9049-C71B14C2DDBF Q33917547-FF1C58FD-725E-46A8-A9A8-52429EAF38D0 Q33943277-CC1DC377-8C50-45BA-8B22-FAAC15594D77 Q35183062-0BACDEBE-9BE9-4293-9641-68F10F2B19A7 Q35625440-0556B072-7602-40F7-A2C8-6C55D6CF27E5 Q35705992-3468BFE5-C941-4FB2-B5CE-C5EC01B8DC24 Q37117628-6C7469E8-1AC7-4FBA-836A-39D716D12E0F Q37274340-A076057B-752F-45BE-875C-C770168C1B38 Q37364509-BAC32026-1281-49B5-9B60-C0A13FCD084F Q37653222-C94970AD-2C6A-47D5-951B-E25F03C9101F Q37866136-989108C6-5CC2-42C8-B0A3-07D3ABB60546 Q37927089-24EA5A0E-753F-4C39-A6C0-44969F9033EE Q38001798-3B198842-7C11-4BCA-BB38-D92B72E598DC Q38094782-CFB47628-94E3-4DAC-A7E8-CAAE89C3DCA0 Q38113583-2DC0F64C-C2DC-423B-AAB8-1098297B494F Q38717560-AD24F088-6A7C-4BE6-A065-3068EE292DC8 Q38892684-6152F35A-E425-4A20-B851-64573CE4C87D Q38893052-2C91C030-7009-47DE-93DF-37ACE208162C Q39302268-EA060E89-B493-4454-9225-7C781FED9E4C Q39506406-40CE082F-5F9C-49D2-9255-B22F81D87531 Q40655660-299BD98E-3275-4F2D-9EE6-86814BB27CE9 Q45731131-A98C93A2-181E-4697-B52A-8E711CF4821B Q48312017-B3B1D6E6-AB18-4FA5-A94D-CE5C27BD5142 Q57809333-8BD193BF-8CDD-4291-BA0B-1DEAA26F8175

P2860

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.

http://www.wikidata.org/entity/Q34360637

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@ast

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@en

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@nl

type

label

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@ast

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@en

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@nl

prefLabel

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@ast

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@en

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@nl

P1433

Q34360637-CCD69D58-B941-4DBD-8443-30B530BAAC4E

P1476

Q34360637-45B005EE-2763-4DC3-A335-C35F30AAAB6F

P2093

Q34360637-0A9EB75F-6E70-4342-9419-A4482EC971C9

Q34360637-537B6C96-64B7-4309-A2C5-D502D399E8C0

Q34360637-6476911D-0545-44AA-ADBA-F30ABE8D76B9

Q34360637-6BA420BA-D36D-4095-99FB-0810BFBC080F

Q34360637-79C8F1FF-2903-4BF1-A73B-7C456A438E4D

Q34360637-833D77D8-4EA4-4035-A2D2-F519581AA16F

Q34360637-88367ED7-DD0B-4921-8921-37589C0C749B

Q34360637-9EAA23B2-34FD-4526-A11D-36181A1B2638

Q34360637-BAEC658F-BE10-4EE0-A463-33B1210F145C

Q34360637-DDEE7605-25A8-4365-8FEA-CD4B83D86743

P2860

Q34360637-03A1C2B5-AA92-49C7-BE8B-C3A87318A57F

Q34360637-234D6C7D-E891-47C9-8D30-0F39141CD094

Q34360637-25BC105F-8656-411A-BB47-6EFF7B9DD3DB

Q34360637-34BF3BC3-C7FA-4E04-BDA9-9B36A17C6942

Q34360637-36A2801A-2180-4E1E-AFCD-527E5E45119D

Q34360637-3A2F523D-5D38-4534-96DF-E98338BFEDCD

Q34360637-513E137B-545E-4A08-82B6-69FA33D806BC

Q34360637-58161E7F-F25C-4841-8A5A-548DCA1F86B7

Q34360637-5ACB4153-BAEB-4A0D-804C-71E7E257575A

Q34360637-882B3184-3317-4BF2-8B43-3D04105BB673

P2888

Q34360637-EDB068C9-6F38-4180-8EC3-B378B20CCC72

P304

Q34360637-AEE92EBA-FA53-4CA5-A521-42A02F3C0DD4

P31

Q34360637-EBEEA283-DE0C-4292-AB79-949C7BC79C1C

P356

Q34360637-7FDE3E3F-CFED-416D-ACD5-C26DA6B9ABE1

P478

Q34360637-A2C5D321-58A7-49AB-BE0B-6C6D9791E3B3

P577

Q34360637-E9AA18F0-2B9A-4256-9D66-96A13C1C8ED2

P5875

Q34360637-A50A01AC-31D0-4826-A071-D2403FCEAB99

P6179

Q34360637-F988A3C3-F6EA-481C-BB9C-7775817A2D91

P698

Q34360637-D572D2AF-586D-46EB-A2DC-0F2423AF6A98

P921

Q34360637-99E929E8-D157-4453-A0EF-6E1BE99CE8C1

P932

Q34360637-C4B31790-D1E9-4594-A3EE-C51C7A1406A2

P356

1476-4598-9-292

P1433

Molecular Cancer

P1476

mTOR signaling is activated by ...... acute myeloid leukemia cells.

@en

P2093

Efi Staikou-Drakopoulou

http://www.w3.org/2001/XMLSchema#string

Efstratios Patsouris

http://www.w3.org/2001/XMLSchema#string

Elias Drakos

http://www.w3.org/2001/XMLSchema#string

Ellen J Schlette

http://www.w3.org/2001/XMLSchema#string

George Z Rassidakis

http://www.w3.org/2001/XMLSchema#string

Ioannis Grammatikakis

http://www.w3.org/2001/XMLSchema#string

Jiang Li

http://www.w3.org/2001/XMLSchema#string

L Jeffrey Medeiros

http://www.w3.org/2001/XMLSchema#string

Panayiotis Panayiotidis

http://www.w3.org/2001/XMLSchema#string

Vasiliki Leventaki

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

Defining the role of mTOR in cancer

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

Molecular mechanisms of mTOR-mediated translational control

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.

P2888

1476-4598-9-292

P304

292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-9-292

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47741844

http://www.w3.org/2001/XMLSchema#string

P6179

1021824700

http://www.w3.org/2001/XMLSchema#string

P698

21067588

http://www.w3.org/2001/XMLSchema#string

P921

P932

2993677

http://www.w3.org/2001/XMLSchema#string